Rankings
▼
Calendar
ALXO FY 2023 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena
ALXO
ALX Oncology Holdings Inc.
$112M
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$170M
Net Income
-$161M
EPS (Diluted)
$-3.74
Cash Flow
Operating Cash Flow
-$130M
Free Cash Flow
-$132M
Stock-Based Comp.
$26M
Balance Sheet
Total Assets
$243M
Total Liabilities
$53M
Stockholders' Equity
$190M
Cash & Equivalents
$22M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$170M
-$127M
-33.6%
Net Income
-$161M
-$123M
-30.2%
← Q4 2022
All Quarters
Q1 2023 →